These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19309222)

  • 21. Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.
    Vasconcelos FC; Silva KL; Souza PS; Silva LF; Moellmann-Coelho A; Klumb CE; Maia RC
    Cytometry B Clin Cytom; 2011 May; 80(3):158-66. PubMed ID: 21520403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Reversal of multidrug-resistance in human leukemia cell line K562/A02 by tyrosine kinase inhibitors].
    Shan XY; Chen BA; Xia GH; Xu WL; Ding JH; Gao C; Sun YY; Wang J; Cheng J; Zhao G; Bao W; Song HH; Gao F; Wang F; Wang XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):90-5. PubMed ID: 20137125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
    Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
    Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells.
    Park J; Kim S; Oh JK; Kim JY; Yoon SS; Lee D; Kim Y
    J Biochem Mol Biol; 2005 Nov; 38(6):725-38. PubMed ID: 16336789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
    Baran Y; Ural AU; Gunduz U
    Hematology; 2007 Dec; 12(6):497-503. PubMed ID: 17852433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Study on the mechanisms of imatinib-resistance of cancer stem-like cells in K562/Vp16 cell line].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):669-73. PubMed ID: 16620554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519.
    Che XF; Nakajima Y; Sumizawa T; Ikeda R; Ren XQ; Zheng CL; Mukai M; Furukawa T; Haraguchi M; Gao H; Sugimoto Y; Akiyama S
    Cancer Lett; 2002 Dec; 187(1-2):111-9. PubMed ID: 12359358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
    Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
    Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells.
    Bonovolias ID; Tsiftsoglou AS
    Oncol Res; 2009; 17(11-12):535-47. PubMed ID: 19806784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
    Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
    Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
    Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia.
    Hallböök H; Barbany G; Aleskog A; Björnberg A; Larsson R; Sundström C; Lindhagen E
    Anticancer Drugs; 2005 Jul; 16(6):631-4. PubMed ID: 15930891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.
    Corrêa S; Binato R; Du Rocher B; Ferreira G; Cappelletti P; Soares-Lima S; Pinto LF; Mencalha A; Abdelhay E
    Epigenetics; 2014 Aug; 9(8):1172-83. PubMed ID: 25089713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
    Giles FJ; Cortes JE; Kantarjian HM
    Curr Mol Med; 2005 Nov; 5(7):615-23. PubMed ID: 16305488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).
    Shen T; Kuang YH; Ashby CR; Lei Y; Chen A; Zhou Y; Chen X; Tiwari AK; Hopper-Borge E; Ouyang J; Chen ZS
    PLoS One; 2009 Oct; 4(10):e7520. PubMed ID: 19841739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia.
    Legrand O; Simonin G; Beauchamp-Nicoud A; Zittoun R; Marie JP
    Blood; 1999 Aug; 94(3):1046-56. PubMed ID: 10419897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Pgp- and MRP-mediated multidrug resistance in leukemia cell lines.
    Gong YP; Liu T; Jia YQ; Qin L; Deng CQ; Yang RY
    Int J Hematol; 2002 Feb; 75(2):154-60. PubMed ID: 11939261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
    Kurzrock R; Talpaz M; Li L; Estrov Z
    Leuk Lymphoma; 2006 Aug; 47(8):1651-64. PubMed ID: 16966279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.